Loading...
XNASCMRX
Market cap329mUSD
Jan 16, Last price  
3.66USD
1D
5.48%
1Q
315.44%
Jan 2017
-20.43%
IPO
-79.86%
Name

Chimerix Inc

Chart & Performance

D1W1MN
XNAS:CMRX chart
P/E
—
P/S
1,015.94
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
12.77%
Rev. gr., 5y
-46.24%
Revenues
324k
-99.04%
1,715,00012,101,00033,720,0004,370,0004,040,00010,762,0005,702,0004,494,0007,216,00012,519,0005,372,0001,979,00033,824,000324,000
Net income
-82m
L
-25,457,000-25,589,000-4,406,000-36,445,000-59,312,000-117,372,000-76,390,000-70,984,000-69,474,000-173,650,000-42,126,000-255,795,000172,167,000-82,095,000
CFO
-69m
L+47.41%
-21,681,000-26,279,000-1,876,000-25,559,000-47,077,000-99,890,000-63,815,000-50,125,000-53,725,000-75,181,000-36,038,000-99,930,000-46,867,000-69,088,000
Earnings
Feb 26, 2025

Profile

Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs include ONC201 a program for treating tumors which harbor the H3 K27M mutation in recurrent diffuse midline glioma patients; ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist that demonstrated enhanced non-competitive DRD2 antagonism relative to ONC201, which is in Phase I clinical trials to treat solid tumors; ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for solid tumors and hematological malignancies, including pancreatic cancer and leukemias; and dociparstat sodium (DSTAT), which inhibits the activities of key proteins implicated in the resistance of acute myeloid leukemia blasts and leukemic stem cells to chemotherapy. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; and SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.
URL
https://www.chimerix.com/
IPO date
Apr 11, 2013
Employees
89
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
324
-99.04%
33,824
1,609.15%
Cost of revenue
93,389
94,210
Unusual Expense (Income)
NOPBT
(93,065)
(60,386)
NOPBT Margin
Operating Taxes
36
Tax Rate
NOPAT
(93,065)
(60,422)
Net income
(82,095)
-147.68%
172,167
-167.31%
Dividends
Dividend yield
Proceeds from repurchase of equity
465
608
BB yield
-0.55%
-0.37%
Debt
Debt current
773
Long-term debt
2,479
3,888
Deferred revenue
Other long-term liabilities
Net debt
(202,013)
(261,299)
Cash flow
Cash from operating activities
(69,088)
(46,867)
CAPEX
(89)
(71)
Cash from investing activities
70,599
70,037
Cash from financing activities
308
(12,725)
FCF
(92,580)
(59,956)
Balance
Cash
182,835
217,334
Long term investments
21,657
48,626
Excess cash
204,476
264,269
Stockholders' equity
(795,428)
(713,678)
Invested Capital
989,759
973,377
ROIC
ROCE
EV
Common stock shares outstanding
88,604
88,776
Price
0.96
-48.25%
1.86
-71.07%
Market cap
85,281
-48.35%
165,124
-69.76%
EV
(116,732)
(96,175)
EBITDA
(93,064)
(60,288)
EV/EBITDA
1.25
1.60
Interest
2,919
Interest/NOPBT